INVESTORS

Stemedica Stem Cell Technologies, Incorporated was formed in 2005 by Maynard and Roger Howe. Stemedica distributes adult stem cell and Stemviva nutraceutical products to restore and enhance wellness. The company was created as a result of assisting a relative in their journey to find treatment solutions to return independence and quality of life after a tragic car accident.

Stemedica is a collaboration of the experience that Russian scientists have accumulated over the past 20+ years treating patients with adult stem cell therapies and the skills of the leadership in creating and operating successful companies. To achieve their vision of providing options for restoring and enhancing quality of life, the leaders at Stemedica purchased the intellectual property and the rights to the adult stem cell technology and recruited a team of professionals respected in their area of expertise.

Stemedica's leadership team brings successes in their respective fields. The team applies purpose-driven scientific, medical, and strategic business thinking to all their activities. The company operates with the highest standards of compliance and professionalism and focuses on corporate and social responsibility as a key aspect of its mission.

Stemedica's operations include patented and proprietary adult stem cell technologies for maximum safety and effectiveness. Stemedica uses only adult stem cells in their manufacturing processes. Stemedica's stem cell products and services incorporate both current Good Manufacturing Practices ("cGMP") and current Good Laboratory Practices ("cGLP"). They also follow FDA guidelines or those of the regulatory agencies in the countries of manufacture and where Licensed Treatment Centers are located.

Treatments using Stemedica's propriety adult stem cell technology and patented nutraceutical products are administered through Licensed Treatment Centers located around the world. These centers must pass a rigorous screening process and comply with specific guidelines are part of their membership in the xxx Association. Stemedica also offers its Stemviva nutraceutical products via their company site.

The team at Stemedica has worked with various strategic partners to develop and introduce processes and methodologies for viable extraction, processing, an transplantation of adult stem cells. Collaborators include Stanford University, Burnham Institute for Medical Research, Beckman Laser Institute, Niels Bohr Institute, and The Federov Eye Institute & Hospital.

Stemedica continues their work with their strategic partners to identify and introduce new options for treating diseases and on jointly developing new therapeutic strategies using adult stem cells. Stemedica expects to become "tissue independent" in the near future. Being "tissue independent" enables Stemedica to manufacture their adult stem cell products solely from Adult Stem Cell Master Cell Banks. These banks will store reserves of adult stems cells ready to be deployed to the Licensed Treatment Centers for immediate use in patient therapy through worldwide Licensed Treatment Centers.

For more information regarding Stemedica Stem Cell Technologies, Incorporated and its Investor opportunities, please contact us at investors@stemedica.com.